Everand Logo

Welcome to Everand!

  • STAT

    Sabin Institute acquires rights to develop vaccines for Ebola and Marburg viruses

    GSK is giving the nonprofit Sabin Vaccine Institute rights to develop vaccines to protect against two species of Ebola and a related virus, Marburg.
    by Helen Branswell Aug 06, 2019 2 minutes
    Nurses working with the WHO prepare to administer vaccines in Mbandaka, Democratic Republic of the Congo, in May 2018 during the launch of the Ebola vaccination campaign.

    The nonprofit Sabin Vaccine Institute is taking over development of vaccines to protect against two species of Ebola and a related virus, Marburg, acquiring the rights from GSK, the two entities announced Tuesday.

    The transfer of the rights for the vaccines will put back into development a vaccine that GSK had shelved after the West African Ebola outbreak of 2014-2016. No money is changing hands; GSK

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

    Related Books & Audiobooks